Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX).
Amgen (AMGN)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Sell rating on Amgen, with a price target of $317.00. The company’s shares closed last Tuesday at $393.17.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 6.4% and a 60.5% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Parabilis Medicines, Inc., Ultragenyx Pharmaceutical, and Arvinas Holding Company.
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $397.95.
